- NCIt
- C5028
Loading cancer entity…
Loading cancer entity…
Clinical trials
110 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04635423 | Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) | completed | Phase 3 | 1,059 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02773719 | Biofields Therapy on Warts(MAGNETIK) | completed | N/A | 62 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02750202 | Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts(TheraVACCS) | completed | Phase 3 | 52 | University of PretoriaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05087849 | Intralesional HPV Vaccine for Condylomata | completed | Phase 1 / Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05889845 | Candin for the Treatment of Common Warts | completed | Phase 3 | 330 | Nielsen BioSciences, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)(FUTURE II) | completed | Phase 3 | 12,167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2025 | clinicaltrials |
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | completed | Phase 2 | 153 | Veradermics, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06915779 | Long Term Follow-up of HPV Vaccine in HIV (CTN 236) | completed | — | 241 | University of British ColumbiaOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06214559 | Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. | completed | N/A | 33 | Swiss Footcare Laboratories - Poderm ProfessionalINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05100043 | Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts | completed | — | 80 | Zagazig UniversityOTHER_GOV | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06700941 | Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment | completed | — | 8,000,000 | Universidad Nacional de ColombiaOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT05896215 | OM202JP Clinical Study of KNP2002 | completed | Phase 2 | 159 | KinoPharma Inc.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05877313 | Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) | completed | Phase 2 | 20 | Sanotize Research and Development corp.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05070754 | Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca | completed | Phase 4 | 17 | Medical University of South CarolinaOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04738734 | CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts | completed | N/A | 150 | Pulse Biosciences, Inc.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04554394 | CellFX System for the Treatment of Cutaneous Non-Genital Warts | completed | N/A | 62 | Pulse Biosciences, Inc.INDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04793529 | Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study | completed | N/A | 60 | Benha UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT02462187 | Topical NVN1000 for the Treatment of External Genital and Perianal Warts | completed | Phase 2 | 108 | Novan, Inc.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05115669 | Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts | completed | N/A | 50 | Karo Pharma ABINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT01746056 | A Comparative Study of Occlusive Heat Patch in the Treatment of Warts | completed | N/A | 73 | Yale UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT04425291 | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,680 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT00189293 | Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts | completed | Phase 4 | 128 | MEDA Pharma GmbH & Co. KGINDUSTRY | 1 | Feb 7, 2022 | clinicaltrials |
| NCT04796090 | Genital Wart and Sexuality in Adolescence | completed | — | 90 | Ankara City Hospital BilkentOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 426 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 502 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 503 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03183765 | Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts | completed | Phase 4 | 48 | Assiut UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT01796821 | Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) | completed | Phase 2 | 138 | G&E Herbal Biotechnology Co., LTDINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03676101 | Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03158220 | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | completed | Phase 3 | 1,212 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT02188004 | The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases | completed | — | 4,691 | Jun ZhangOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | completed | Phase 2 | 157 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | completed | Phase 2 | 159 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT00543543 | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) | completed | Phase 3 | 14,840 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01047345 | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) | completed | Phase 3 | 924 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01651949 | Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) | completed | Phase 3 | 2,520 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT03625960 | Cantharone for the Treatment of Perenial Warts | completed | Phase 4 | 12 | Wayne State UniversityOTHER | 0 | Aug 10, 2018 | clinicaltrials |
| NCT01536834 | Safety & Performance Study of Verruca Treatment Device | completed | N/A | 35 | Reckitt Benckiser LLCINDUSTRY | 1 | Oct 11, 2017 | clinicaltrials |
| NCT02622568 | Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study | completed | Phase 4 | 28 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 8, 2017 | clinicaltrials |
| NCT02748902 | Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands. | completed | Phase 1 | 16 | Neal D. Bhatia, MDOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00092482 | Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) | completed | Phase 3 | 3,882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 | clinicaltrials |
| NCT00517309 | Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)(FUTURE) | completed | Phase 3 | 1,877 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 | clinicaltrials |
| NCT02558803 | HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3 | completed | N/A | 1,305 | Regenstrief Institute, Inc.OTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT02551887 | HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts | completed | N/A | 647 | Regenstrief Institute, Inc.OTHER | 0 | Mar 11, 2016 | clinicaltrials |
| NCT02483455 | ALC-919 For The Treatment Of Common Warts | completed | Phase 2 | 21 | Veloce BioPharma LLCINDUSTRY | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00851643 | Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) | completed | Phase 1 | 158 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 3, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 11, 2026source: clinicaltrials